Gray KM, Sonne SC, McClure EA, Ghitza UE, Matthews AG, McRae-Clark A L, Carroll KM, Potter JS, Wiest K, Mooney LJ, Hasson A, Walsh S L, Lofwall M R, Babalonis S, Lindblad RW, Sparenborg S, Wahle A, King JS, Baker NL, Tomko RL, Haynes LF, Vandrey RG, & Levin FR (2017). A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults. Drug Alcohol Depend 117:249-257.
https://www.sciencedirect.com/science/article/pii/S0376871617302624

 

Hartung, D, McCarty, D, Fu, R, Wiest, K, Chalk, M, Gastfriend, DR (2014) Extended-release naltrexone for alcohol and opioid dependence: A meta-analysis of healthcare utilization studies, Journal of Substance Abuse Treatment. 47(2):113-21.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4110954/pdf/nihms603325.pdf

 

Hser YI, Evan E, Huang D, Weiss R, Saxon, A, Carroll K, Woody G, Liu D, Wakim P, Matthews
A, Hatch-Maillette M, Jelstrom E, Wiest K, McLaughlin P, Ling W (2016). Long-term Outcomes after Randomization to Buprenorphine/Naloxone versus Methadone in A Multi-site Trial Addiction 111(4):695-705.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4801718/pdf/nihms740716.pdf

 

Hser YI, Saxon AJ, Huang D, Hasson A, Thomas C, Hillhouse M, Jacobs P, Teruya C, McLaughlin P, Wiest K, Cohen A, Ling W (2014). Treatment Retention among Patients Randomized to Buprenorphine/Naloxone Compared to Methadone in A Multi-site Trial. Addiction 109(1):79-87.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3947022/pdf/nihms519619.pdf

 

Klimas J, Muench J, Wiest K, Croff R, Rieckman T, McCarty D (2015) Alcohol screening among opioid agonist patients in a primary care clinic and an opioid treatment program. J Psychoactive Drugs. 47(1):65-70.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741092/pdf/nihms754812.pdf

 

Korthuis PT, Feaster DJ, Gomez ZL, Das M, Tross S, Wiest K, Douaihy A, Mandler RN, Sorensen JL, Colfax G, McCarty D, Cohen SE, Penn PE, Lape D, Metsch LR. (2012) Injection Behaviors among Injection Drug Users in Treatment: the Role of Hepatitis C Awareness. Addictive Behaviors. 37(4):552-5.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3288438/pdf/nihms342600.pdf

 

Ling W, Hillhouse M, Saxon A, Mooney L, Thomas C, Ang A, Matthews A, Hasson A. Annon J, Sparenborg S, Liu D, McCormack J, Church S, Swafford W, Drexler K, Schuman C, Ross S, Wiest K, Korthuis P, Lawson W, Brigham G, Knox P, Dawe M. (2016) Buprenorphine+Naloxone plus Naltrexone for the Treatment of Cocaine Dependence: The Cocaine Use Reduction with Buprenorphine (CURB) Study. Addiction 111(8):1416-1427.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4940267/pdf/nihms767093.pdf

 

Lones CE, Bond GR, McGovern MP, Carr K, Leckron-Myers T, Hartnett T, Becker DR (2017) Individual Placement and Support (IPS) for Methadone Maintenance Therapy Patients: A Pilot Randomized Controlled Trial Adm Policy Ment Health 44(3):359-364.
https://link.springer.com/article/10.1007/s10488-017-0793-2

 

Potter JS, Marino EN, Hillhouse MP, Nielsen S, Wiest K, Canamar CP, Martin JA, Ang A, Baker R, Saxon AJ, Ling W. (2013) Buprenorphine/Naloxone and Methadone Maintenance Treatment Outcomes for Opioid Analgesic, Heroin, and Combined Users: Findings from Starting Treatment with Agonist Replacement Therapies (START). J Stud Alcohol Drugs. 74(4): 605-13. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3711351/pdf/jsad605.pdf

 

Richardson R, Wiest K. (2015) A preliminary study examining nutritional risk factors, body mass index, and treatment retention in opioid-dependent patients. J Behavioral Health Services & Research. 42(3):401-8.
https://link.springer.com/article/10.1007/s11414-013-9371-x

 

Saxon AJ, Ling W, Hillhouse MP, Thomas C, Hasson A, Doraimani G, Tasissa G, Lokhnygina Y, Leimberger J, Bruce RB, McCarthy J, Wiest K, McLaughlin P, Bilangi R, Cohen A, Woody G, Jacobs P. (2013) Buprenorphine/Naloxone and Methadone Effects on Laboratory Indices of Liver Health: a Randomized Trial. Drug and Alcohol Depend, 128(1-2):71-6. doi: 10.1016/j.drugalcdep.2012.08.002.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3543467/pdf/nihms405369.pdf

 

Teruya C, Schwartz RP, Mitchell SG, Hasson AL, Thomas C, Buoncristinani SH, Hser YI, Wiest K, Cohen AJ, Glick N, Jacobs P, McLaughlin P, Ling W (2014) Patient Perspectives on Buprenorphine/Naloxone: A Qualitative Study of Retention During the Starting Treatment with Agonist Replacement Therapies (START) Study J Psychoactive Drugs, 46(5)412-425.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4220245/pdf/nihms615520.pdf

 

Wiest KL, Asphaug VJ, Carr KE, Gowen E, Hartnett TT (2015) Massage impact on pain in opioid-dependent patients in substance-use treatment. Int J Ther Massage Bodywork 8(1):12-24.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4353208/pdf/ijtmb-8-12.pdf

 

Wiest KL, Colditz JB, Carr K, Asphaug VJ, McCarty D, and Pilkonis PA (2014) Pain and emotional distress among substance-use patients beginning treatment relative to a representative comparison group. J Addict Med 8(6):407-14.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4221468/pdf/nihms-610784.pdf